Therapeutic approaches aimed at re-educating tumor-associated macrophages into immunostimulatory cells (Molgora and Colonna, 2021) may involve targeting the macrophage PI3Kγ intracellular signaling pathway (Zheng and Pollard, 2016), which inhibits NFκB activation through Akt and mTOR (Kaneda et al., 2016), thereby inducing an anti-inflammatory program that promotes immune suppression. The gene discussed is AKT1; the disease is neoplasm.